A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn's Disease
A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn's Disease
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease.
Study periods for the intervention-specific appendix (ISA) will be as follows:
The study will last about 74 weeks and may include up to 19 visits.
Participants screened in the MACARONI-23 Platform study could be randomized to mirikizumab to participate in this intervention specific arm of the study.
Inclusion Criteria:
Exclusion Criteria:
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Los Angeles, California 90048, United States
310-248-8516
Morristown, New Jersey 07960, United States
New York, New York 10021-5663, United States
New York, New York 10032, United States
Curitiba-PR, 80250-060, Brazil
+55 (41) 2108-3861
Israel, 70300, Israel
Alessandria, 15121, Italy
Florence, 50139, Italy
Roma, CAP 00161, Italy
Kashiwa-shi, 277-0871, Japan
81120023812
Setagaya-ku, 157-8535, Japan
81120023812
Nordbyagen, 01474, Norway
+47 67960335
Lisbon, 1649-035, Portugal
Headington, OX3 9DU, United Kingdom
London, WC1N 3JH, United Kingdom
860-837-5591
404-727-4542
317-274-5858
617-355-6058
973-971-6489
646-962-7162
212-659-9443
937-641-5605
973-971-7747
802-656-9402
206-987-1293
3224774795
+32 2 764 19 33
3293321338
+55 19 3343-8465
55(62) 98607-3907
+55 51 3359-6331
+55 51 3214-8143
+55 (27) 999036155
1-902-470-7009
519-685-8500 x56074
+972528709824
+972-39253039
972526274987
+39 0131206893
"39 0352673448 39 0352674553"
39 3313198290
39 055-5662950
393400968832
393404111671
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
+31 (0)10 70 36111
+4722117611/ +4790108309
4773553497
+48517191061
+48 668 171 443
82234100641
Contact Number: 821092233320
+ 393465970480
01865 231592
+0161 701 6948
0114 2267980